ASCENTAGE PHARMA GROUP INTERNATIONAL
AAPG · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $0 |
| % Growth | 48.9% | -81% | 939% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $1 | $0 |
| % Margin | 90.7% | 91.1% | 98.2% | 84.4% |
| R&D Expenses | $1 | $1 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | -$1 | -$1 | $0 | -$1 |
| % Margin | -237.1% | -361.2% | 22.8% | -671.1% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$1 | -$1 | $0 | -$1 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$1 | -$1 | $0 | -$1 |
| % Margin | -252.8% | -362.3% | 19.8% | -660% |
| EPS | -1.73 | -1.82 | 0.56 | -1.8 |
| % Growth | 4.9% | -425% | 131.1% | – |
| EPS Diluted | -1.73 | -1.82 | 0.55 | -1.8 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | $0 | -$0 |
| % Margin | -219.9% | -336.8% | 27.9% | -621.4% |